Stocks Health care SVRA
NASDAQ · Health careSavara Inc (SVRA)
It posted a net loss of $152.7M. In fiscal 2025 capital spending exceeded operating cash flow by $101.1M. At September 30, 2026 it held $29.8M in cash against $30.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Savara Inc
- Net worth
- Savara Inc has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $107.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2020 revenue was $257K, with a net loss of $49.6M.
- Cash flow
- In fiscal 2025 operations used $101M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Savara Inc's next report is expected around March 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Savara Inc does
Savara Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SVRA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$118.8M | -$0.53 | -$101.1M |
| 2024 | n/a | -$95.9M | -$0.48 | -$89.1M |
| 2023 | n/a | -$54.7M | -$0.33 | -$51.4M |
| 2022 | n/a | -$38.2M | -$0.25 | -$34.6M |
| 2021 | n/a | -$43M | -$0.32 | -$40.1M |
| 2020 | $257K | -$49.6M | -$0.84 | -$39.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Savara Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- August 11, 2026
- August 11, 2026
- June 8, 2026
- May 12, 2026
- April 24, 2026
- April 24, 2026Additional proxy material DEFA14A
- April 24, 2026Proxy statement DEF 14A
- April 10, 2026Preliminary proxy statement PRE 14A
- March 13, 2026
Insider trades
What the people running Savara Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 24, 2026 | Parker Braden C.Chief Commercial Officer | Shares withheld for tax | 29,323 | $148.7K |
| July 15, 2026 | Lutz Robert MatthewChief Fin. & Operating Officer | Received as pay | 35,000 | - |
| June 22, 2026 | Lowrance David LChief Financial Officer | Exercised options | 75,000 | $119.3K |
| June 22, 2026 | Lowrance David LChief Financial Officer | Shares withheld for tax | 21,682 | $119.3K |
| June 22, 2026 | Lowrance David LChief Financial Officer | Exercised options | 129,350 | $159.1K |
| June 22, 2026 | Lowrance David LChief Financial Officer | Shares withheld for tax | 28,928 | $159.1K |
| June 22, 2026 | Lowrance David LChief Financial Officer | Exercised options | 56,937 | $63.2K |
| June 22, 2026 | Lowrance David LChief Financial Officer | Shares withheld for tax | 11,491 | $63.2K |
Who owns SVRA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Growth Equity Opportunities 17, LLC13D, may seek influence with 12 related filers | 12% | November 14, 2025 |
| Bain Capital Life Sciences Fund II, L.P.13D, may seek influence with 2 related filers | 9.99% | March 27, 2025 |
| Venrock Healthcare Capital Partners III, L.P.13G, passive with 6 related filers | 9.9% | February 17, 2026 |
| Dapice Joshua J.13G, passive with 28 related filers | 6.9% | February 5, 2026 |
| Deerfield Mgmt, L.P.13G, passive with 3 related filers | 6.74% | November 5, 2025 |
| TCG Crossover GP I, LLC13G, passive with 2 related filers | 6.1% | February 17, 2026 |
| James N. Topper13G, passive with 16 related filers | 5% | November 27, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 181 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| NEA Management Company, LLC | 24,471,264 | 0 |
| Bain Capital Life Sciences Investors, LLC | 17,600,621 | 0 |
| Venrock Adviser, LLC | 14,745,943 | +1,005,568 |
| Nantahala Capital Management, LLC | 13,953,620 | +6,608,837 |
| Deerfield Management Company, L.P. | 13,569,000 | 0 |
| BlackRock, Inc. | 12,494,498 | +1,203,313 |
| TCG Crossover Management, LLC | 12,362,205 | 0 |
| Frazier Life Sciences Management, L.P. | 9,720,852 | 0 |
| Polar Capital Holdings Plc | 9,541,786 | 0 |
| Vanguard Capital Management LLC | 7,932,545 | +148,632 |
| State Street Corp | 6,553,348 | -154,336 |
| Marshall Wace, Llp | 6,256,989 | +1,742,641 |
| Rtw Investments, LP | 5,952,380 | 0 |
| Woodline Partners LP | 4,245,119 | 0 |
| Orbimed Advisors LLC | 3,959,900 | +3,324,900 |
| Geode Capital Management, LLC | 3,872,133 | +277,653 |
| Spruce Street Capital LP | 3,452,576 | +69,401 |
| Rosalind Advisors, Inc. | 3,178,121 | -25,600 |
| Emerald Advisers, LLC | 3,148,439 | -222,846 |
| Pictet Asset Management Holding SA | 2,763,055 | +487,674 |
Insiders
12 insiders reported holding 6,394,687 shares in total, about $31.5M at the last price.
| Holder | Shares |
|---|---|
| Ramsay David ADirector | 2,533,642 |
| Pauls MatthewCHIEF EXECUTIVE OFFICER, Director | 1,188,050 |
| Lowrance David LChief Financial Officer | 536,032 |
| McCabe Kathleen R.Chief Legal Officer | 519,232 |
| Erickson AnneChief Business Officer | 371,712 |
| Lutz Robert MatthewChief Fin. & Operating Officer | 328,977 |
| McCracken Joseph SDirector | 302,644 |
| Wasfi YasmineChief Medical Officer | 168,008 |
| Hawkins Richard JDirector | 161,326 |
| Elam Nevan CDirector | 106,887 |
Questions about SVRA
What does Savara Inc do?
Savara Inc is a company in the Health care sector, listed on NASDAQ as SVRA. Its shares trade on NASDAQ under the ticker SVRA.
What is Savara Inc's net worth?
Savara Inc has a market value (market cap) of $1B at the latest share price, and shareholders' equity of $107.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Savara Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $152.7M.
When did Savara Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Savara Inc's next earnings report?
Savara Inc's next report is expected around March 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SVRA with
Follow SVRA
Get an email when Savara Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Savara Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.